RecruitingNCT07227818
NBI-1117568 to help prevent relapse in adults with schizophrenia
About this title
Read the official source — NCT07227818This study evaluates the safety and effectiveness of NBI-1117568 for people with schizophrenia.
Medication studyAges 18–65United States + Serbia
Understand this study
What is this study about?
This study evaluates the safety and effectiveness of NBI-1117568 for people with schizophrenia.
Who could participate?
Listed age limits: 18 years to 65 years.
What will I do during this study?
Everyone first receives open-label NBI-1117568 during a stabilization period. Participants who have a stable response are then randomly assigned to continue NBI-1117568 or switch to placebo (an inactive comparison treatment) during the double-blind phase.
- Listed locations
- Garden Grove and 24 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: December 16, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 560
- Sponsor
- Neurocrine Biosciences
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Serbia
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT07227818
- Official title
Show the full official title
A Phase 3, Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Assess the Efficacy of NBI-1117568 in Preventing Relapse of the Symptoms of Schizophrenia and to Assess the Safety and Tolerability of NBI-1117568 in Adults With Schizophrenia
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Garden Grove, United States · La Habra, United States · Lemon Grove, United States
20 more locations
- Oceanside, United States
- Torrance, United States
- West Hills, United States
- Hollywood, United States
- Maitland, United States
- Miami, United States
- Tampa, United States
- West Palm Beach, United States
- Atlanta, United States
- Boston, United States
- Flowood, United States
- Marlton, United States
- Cedarhurst, United States
- New York, United States
- The Bronx, United States
- DeSoto, United States
- Bellevue, United States
- San Juan, Puerto Rico
- Gornja Toponica, Serbia
- Kragujevac, Serbia
Interested in joining this study?
Questions about this study
What is this study about?
This study evaluates the safety and effectiveness of NBI-1117568 for people with schizophrenia.
Who is behind this study?
The study sponsor is Neurocrine Biosciences, a biotech company.
Does this study involve medication?
Yes. The study involves medication, including NBI-1117568 and Placebo.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as recruiting.
